Advertisement

Bristol-Myers Squibb and Pfizer, Inc have announced that they will be presenting 22 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at the ESC (European Society of Cardiology) Congress 2015, to be held August 29 to September 2 in London.

DelMar Pharmaceuticals, Inc. has been invited to present an overview of their clinical strategy with VAL-083 (dianhydrogalactitol) as a potential treatment for non-small cell lung cancer ("NSCLC") at the 16th World Conference on Lung Cancer (WCLC 2015) being held from September 6 - 9 in Denver.

Helix BioPharma Corp. announced that an abstract for its lead lung cancer candidate L-DOS47 has also been selected for oral presentation at WCLC) 2015.

Advertisement
Advertisement